Table 2.
Clinical and histopathologic characteristics of patients grouped by AR expression.
| Characteristics | AR <10% (n = 30) | AR ≥10% (n = 132) | p-value |
|---|---|---|---|
| Age (years)* | 45.30 ± 11.04 | 47.27 ± 9.85 | 0.335 |
| Menopausal Status | 0.043 | ||
| Premenopausal | 10 (33.3%) | 71 (53.8%) | |
| Postmenopausal | 20 (66.7%) | 61 (46.2%) | |
| Histologic type | 0.353 | ||
| IDC | 30 (100.0%) | 124 (93.9%) | |
| Other | 0 (0.0%) | 8 (6.1%) | |
| Clinical stage | 0.377 | ||
| II | 13 (43.3%) | 69 (52.3%) | |
| III | 17 (56.7%) | 63 (47.7%) | |
| Clinical T stage | 0.873 | ||
| cT2 | 20 (66.7%) | 90 (68.2%) | |
| cT3-4 | 10 (33.3%) | 42 (31.8%) | |
| Clinical N stage | 0.412 | ||
| cN0 | 5 (16.7%) | 18 (13.6%) | |
| cN1 | 12 (40.0%) | 70 (53.0%) | |
| cN2-3 | 13 (43.3%) | 44 (33.3%) | |
| ER status | <0.001 | ||
| Positive | 8 (26.7%) | 87 (65.9%) | |
| Negative | 22 (73.3%) | 45 (34.1%) | |
| PR status | <0.001 | ||
| Positive | 4 (13.3%) | 79 (59.9%) | |
| Negative | 26 (86.7%) | 53 (40.2%) | |
| HER2 status | 0.015 | ||
| Positive | 9 (30.0%) | 72 (54.6%) | |
| Negative | 21 (70.0%) | 60 (45.5%) | |
| Molecular subtype | <0.001 | ||
| HR+/HER2− | 6 (20.0%) | 50 (37.9%) | |
| HER2+ | 9 (30.0%) | 72 (54.6%) | |
| TNBC | 15 (50.0%) | 10 (7.6%) | |
| Ki-67 | 0.006 | ||
| <30% | 6 (20.0%) | 63 (47.7%) | |
| ≥30% | 24 (80.0%) | 69 (52.3%) |
Data are described as numbers of patients, with percentages in the parentheses. *Those data are described as mean ± standard deviation. AR, androgen receptor; IDC, invasive ductal breast carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; Ki-67, cellular proliferation index; HR, hormone receptor; TNBC, triple-negative breast cancer.